Sandoz, the Novartis generics and biosimilars division, has announced plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe.   “This plan is a great example of government and the private sector working closely together to protect the long-term interests of patients in Europe and beyond,” commented Sandoz CEO Richard Saynor. “Antibiotics are the backbone of modern medicine and our Kundl fac...